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Objective: To identify poorly compliant glaucoma patients, using the Eye-Drop Satisfaction 
Questionnaire (EDSQ).
Methods: This was an observational cross-sectional study with compliance data collected 
by an electronic monitoring device. Patients with primary open-angle glaucoma or ocular 
hypertension completed the EDSQ, a six-dimension self-reported questionnaire addressing 
“treatment concern”, “disease concern”, “patient–clinician relationship”, “positive beliefs”, 
“treatment convenience”, and “self-declared compliance”. A Bayesian network (BN) was 
applied to explore compliance associations with EDSQ.
Results: Among 169 patients who completed the EDSQ, 113 had valid Travalert® data, of whom 
25 (22.1%) demonstrated low compliance. All six EDSQ dimensions were associated directly, 
or indirectly, with compliance. Two profiles exhibited low compliance, ie, patients aged younger 
than 77.5 years with a poor patient–physician relationship and self-declared poor compliance and 
patients aged older than 77.5 years with a poor patient–physician relationship and self-declared 
good compliance. The third profile showed high compliance, ie, patients aged younger than 
77.5 years with a good patient-physician relationship and self-declared good compliance.
Conclusion: Our results confirm a central role for the patient–physician relationship in the 
compliance process. Age, self-declared compliance, and patient satisfaction with the patient–
physician relationship are all dimensions worth exploring before glaucoma medication is switched 
or proceeding to laser treatment or surgery.
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Introduction
Glaucoma is the second leading cause of blindness globally.1 From 1991 to 1999, 
primary open-angle glaucoma prevalence increased from 4.6% to 13.8% among the 
elderly.2 Its treatment is aimed essentially at lowering intraocular pressure (IOP) by eye 
drop instillations, reserving surgery or laser surgery for the most severe cases. Several 
classes of medicine are available, ie, prostaglandin analogs, miotics, beta-blockers, 
alpha-adrenergic agonists, and carbonic anhydrase inhibitors. Glaucoma treatment 
principles and options have been reported by the European Glaucoma   Society.3 Success-
ful treatment depends upon strict lifetime adherence to the instillation schedule. Thus, 
higher adherence is associated with better IOP control, on average,4 and a lower risk 
of eventual blindness.5 However, patients perceive few symptoms in the early stages, 
whereas eye drops (with potential side effects) are needed daily and may become a 
burden, leading to poor treatment adherence.6Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Adherence to treatment schedules has been examined 
by numerous studies in glaucoma, using various methods. 
For example, the medication possession ratio, determining 
the mean proportion of days during a given period when 
patients possess medication, was calculated from insurance 
claims or prescription databases,7–9 and from electronic 
devices capturing drop counts.10 Alternatively, patients’ 
self-declared compliance was obtained from interviews11–13 
or standardized questionnaires.8,14–18 Another difference 
between studies were noncompliance criteria, eg, patients 
who missed more than two doses per week18 or possessed 
insufficient drops for the specified period (medication 
  possession ratio , 1).5 With this array of methodology 
across different drug classes and countries, compliance 
rates varied from 59% to 77%.7,11,14,16,18–21 More informally, 
imperfect compliance is consistently reported among glau-
coma patients.
To improve glaucoma care, it is critical to identify 
patients who may not adhere to treatment. Factors conducive 
to noncompliance have been explored. For example, complex 
dosing regimens have an impact on compliance.19,22 However, 
barriers cited by most studies relate to patients’ perception 
and knowledge about their illness and its treatment.7,11,16,18 
These considerations prompted the development of an 
  Eye-Drop Satisfaction Questionnaire (EDSQ) which asks 
patients to self-report their satisfaction and compliance with 
topical ophthalmic treatments.23 Replies to these questions 
should be relevant to an exploration of noncompliance in 
glaucoma patients.
A suitable technique for analyzing such data is a   Bayesian 
network (BN) which facilitates the representation and 
manipulation of information. A BN is a directed acyclic graph 
representing relationships between variables (nodes in the 
graph) with a related set of conditional probability tables that 
characterize local dependencies between the various nodes. 
Hence, it provides a powerful tool to study interdependencies 
between complex processes, such as patient behavior. The 
objective of this study was to identify poorly compliant 
glaucoma patients by exploring EDSQ data.
Methods and materials
The present survey was conducted according to French law. 
The protocol was reviewed and approved by the Comité 
consultatif sur le traitement de l’information en matière de 
recherche dans le domaine de la santé and the Commission 
nationale informatique et liberté.24–26 This research was 
conducted according to the tenets of the Declaration of 
Helsinki.27
Patients and study design
This multicenter study was conducted in France by 17 
  ophthalmologists (at 17 sites) specializing in the treatment 
of glaucoma, who also prescribed Travalert®, a   computerized 
device that reminds patients to instill eye drops, assists 
with instillations, and records dosing times. The accuracy 
of Travalert for measuring treatment adherence has been 
described elsewhere.28,29 Ophthalmologists recruited patients 
who used the device and gave informed consent before 
participating. At the inclusion visit, the ophthalmologist 
completed a medical questionnaire for each patient.   General 
comorbidities (cardiovascular, central nervous system, 
hepatic diseases, diabetes, pulmonary diseases, digestive 
  diseases, others) and eye comorbidities (macular degen-
eration, diabetic retinopathy, retinal detachment, cataract, 
uveitis, others) were collected.
Patients included used the Travalert device for at least 
eight weeks, were 18 years of age or older, and diagnosed 
with either primary open-angle glaucoma (including   juvenile 
glaucoma, exfoliative glaucoma, pigmentary glaucoma, 
or normal-tension glaucoma) or high IOP. Patients with 
  secondary glaucoma (congenital glaucoma,   inflammatory 
glaucoma, angle-closure or narrow-angle glaucoma   following 
cataract surgery), or took an anticoagulant three times per 
day or more, and patients with chronic eye dryness requiring 
instillations of more than five drops a day, were excluded.
According to a previous clustering analysis, data collected 
with the Travalert device allowed the patient sample to be 
categorized according to three compliance profiles, ie, high 
compliance, moderate compliance, or low compliance.4
Eye-Drop Satisfaction Questionnaire
The EDSQ is a self-assessment questionnaire that assesses 
patient satisfaction and compliance with eye-drop treatment 
for glaucoma or IOP. Its development in France and the UK 
involved two steps. First, patient and clinician interviews 
were conducted to determine an appropriate conceptual 
model and obtain patients’ ratings. Second, a comprehen-
sion evaluation was undertaken to ensure the questionnaire’s 
clarity, ease of comprehension, and cultural equivalence.23 
The questions are scored on a 1–5 Likert scale.
A scoring algorithm for the 21-item questionnaire was 
also developed and shown to have satisfactory validity and 
reliability.30 The EDSQ algorithm computes scores (0–100) 
for six dimensions of attitudes towards eye-drop treatment, 
ie, “treatment concern” (five items), “disease concern” (two 
items), satisfaction with the “patient–clinician relationship” 
(five items); “positive beliefs” (three items), “treatment Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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convenience” (three items), and “self-declared compliance” 
(three items). High scores represented high dimension 
concerns.
EDSQ data were collected at the follow-up visit when the 
Travalert data were collected from the patient.
statistical analyses
Population analysis and oversampling strategy
Patients who completed the EDSQ and provided   sufficient 
Travalert data to define their compliance profile were 
included in the analysis. An oversampling method was 
adopted to increase the ability of the BN to identify risk 
  factors for noncompliance.31 This involved randomly 
selecting patients from the smallest group (low compliance) 
as successive replacements to create a sample equal to the 
largest group (high and moderate compliance). A uniform (all 
patients had the same probability to be sampled, without site 
stratification) sampling method was used because the small 
sample size did not authorize strong distribution estimates. 
The objective was to achieve a ratio of one patient with low 
compliance to one with high or moderate compliance.
Bayesian networks
A BN is a form of probabilistic graph, representing a joint 
probability distribution of a set of variables with explicit 
independency assumptions. It is a directed acyclic graph, 
ie, without cycles and has edges that are orientated. It is 
composed of a set of nodes (each node represents one variable 
modeling the process of interest) and a set of conditional 
probability tables encoding local dependencies between the 
nodes/variables. BNs are often used to identify structure of 
the information when very few hypotheses could be identified 
a priori.
A BN was constructed to identify poor compliers by 
discriminating between low-compliance and moderate- or 
high-compliance patients. Center was not included in the BN 
due to the numbers of patients per center being too small. 
The network structure (relationships between variables) was 
based on data by applying the “taboo order” algorithm to 
scores derived from the BN learning algorithm.32 A score 
denoted the minimum description length, and was two fold; 
the first part qualified the network with respect to its structural 
complexity and the second part measured the goodness-of-
fit between the network and the data. With a given order of 
nodes, it is simple to determine the best BN, because each 
node looks to its best parent, ie, its immediate predecessor 
amongst all available nodes. The goal of taboo order is to 
search for the order of nodes resulting in the best BN value 
(highest minimum description length score), and to this end 
uses taboo search.33 This algorithm is fully driven by the data, 
is fully inferential, and with no clinical expert input. Missing 
data were inferred according to the expectation-maximization 
structural method. Because BN requires categoric variables, 
EDSQ scores were categorized by dichotomizing (thresholds 
were determined while estimating the BN) them according 
to a decision tree-based algorithm aimed at maximizing 
the detection of low compliance. Descriptive analyses were 
performed using SAS for Windows v9.2 (SAS Institute, Inc., 
Cary, NC) and BN was obtained using Bayesialab v4.6.1 
(Bayesia, Mayenne, France).
Results
Of the glaucoma specialists, 88.2% were male, 29.4% worked 
in a public hospital setting, and had qualified on average 
16.5 years earlier. They declared 36.7 visits per week for pri-
mary open-angle glaucoma and 11.4 for ocular hypertension. 
Among 179 patients screened, 169 (94.4%) completed the 
EDSQ at the visit. One hundred and forty patients (78.2%) 
used the Travalert, brought it back to the visit, with successful 
data transfer to the investigator computer. Among the 140 
transferred files, 113 (80.7%) provided reliable data (compli-
ance fully documented for at least eight weeks) sufficient for 
the classification algorithm. Technical criteria to participate 
to the clustering algorithm have been published elsewhere.4
Patient characteristics
The characteristics of patients meeting the inclusion criteria 
are presented in Table 1. The gender ratio was balanced, mean 
age was 65.1 years, 16.6% had undergone surgery for primary 
open-angle glaucoma, and 10.1% had received laser therapy. 
At the inclusion visit, worst eye mean IOP was 16.4 mmHg 
and best eye mean visual acuity was 8.80. The frequency of 
high compliance (56.6%) was much greater than that of low 
compliance (22.1%).
Bayesian networks
The BN (Figure 1) shows three nodes directly related 
to Travalert-identified compliance, ie, patient–clinician 
relationship, self-declared compliance, and age. Treatment 
concern has three drivers, which are disease concern, gender, 
and positive beliefs, and itself impacts on the patient–clinician 
relationship. Treatment convenience impacts on positive 
beliefs, which impacts upon self-declared compliance.
Two subgroups of patients had a noticeable distribution 
across groups defined according to treatment concern score 
(Table 2). First, women with a disease concern score .47.018 Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of patients included in the study (n = 169)
Age, years MD 
Mean (SD) 
Median (range)
1 
65.1 
67.5
 
(11.8) 
(18–89)
Gender, n (%) MD 
Male 
Female
1 
83 
85
 
(49.1) 
(50.3)
Comorbidities, n (%) Ocular 
Other
19 
50
(11.2) 
(29.6)
Nonmedicated treatment  
of glaucoma/intraocular  
high pressure, n (%)
MD 
surgery 
Laser
1 
28 
17
 
(16.6) 
(10.1)
intraocular pressure, mmhg 
(worst eye)
MD 
Mean (SD) 
Median (range)
5 
16.42 
16
 
(3.87) 
(9–40)
Visual acuitya (best eye) MD 
Mean (SD) 
Median (range)
13 
8.80 
10
 
(1.98) 
(1–12)
Compliance profiles, n (%) MD 
Low compliance 
Moderate compliance 
high compliance
56 
25 
24 
64
 
(22.1) 
(21.2) 
(56.6)
Note: aDecimal scale. 
Abbreviations: MD, missing data; SD, standard deviation.
Disease concern
Patient–clinician relationship
Travalert identified compliance
Gender
Positive beliefs
compliance
Treatment convenience
age
Marital status
Treatment concern
Figure 1 Bayesian network diagram predicting compliance as measured by Travalert®, obtained by oversampling data.
were markedly more likely to have a treatment concern score 
of .24.197 than the total population. Second, patients with 
a disease concern score of ,47.018 and a positive beliefs 
score .61.335 were also more likely to have a treatment 
concern score of .24.197.
When compared with the total population, a higher per-
centage of patients with a treatment concern score ,24.197 
had a patient–clinician relationship score .67.5 (Table 3). 
More patients with a treatment convenience score of ,69.397 
had a positive beliefs score ,61.335 compared with the total 
analysis population (Table 4). A higher percentage of patients 
with a positive beliefs score ,61.335 had a self-declared 
compliance score ,89.583, as compared with the analyzed 
population (Table 5).
Compliance identified by Travalert was related to three 
variables, these being age, patient–clinician   relationship, 
and self-declared compliance (Table 6). Three different 
combinations of these characteristics were relevant to 
low or high compliance, compared with the total sample 
(Figure 2). Low compliance was associated with two 
  combinations; first, age ,77.5 years, a self-declared 
compliance score ,89.5, and a patient–clinician relationship 
score ,67.5 and, second, age .77.5 years, a self-declared com-
pliance score of .89.5, and a patient–clinician relationship 
score ,67.5. By contrast, high compliance was associated with 
age ,77.5 years, a self-declared compliance score .89.5, and 
a patient–clinician relationship score .67.5.
Discussion
The primary objective of this study was to identify glaucoma 
patients who adhered poorly to treatment by recording their Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 2 Associations between treatment concern scores and 
positive beliefs scores, disease concern scores, and gender
Positive 
beliefs 
score
Disease 
concern 
score
Gender Treatment concern score 
(n, %)
#24.197 .24.197
#61.335 #47.018 Female 5 (55.6) 4 (44.4)
#61.335 #47.018 Male 9 (60.0) 6 (40.0)
#61.335 .47.018 Female 5 (31.3) 11 (68.8)
#61.335 .47.018 Male 10 (52.6) 9 (47.4)
.61.335 #47.018 Female 16 (88.9) 2 (11.1)
.61.335 #47.018 Male 31.5a (85.1) 5.5a (14.9)
.61.335 .47.018 Female 13 (36.6) 22.5a (63.4)
.61.335 .47.018 Male 21 (79.2) 5.5a (20.8)
Total 110.5a (62.8) 65.5a (37.2)
Notes:  a0.5  frequencies  due  to  missing  data  imputation.  Eye-Drop  Satisfaction 
Questionnaire scores ranged from 0 to 100. Higher dimension scores reflect more 
of the attribute implied by the name (eg, higher concern about disease). Threshold 
values fixed by the Bayesian network algorithm.
daily instillation times and eye drop counts objectively, 
with a computerized bottle holder (Travalert). In a previous 
analysis, patient demographics and baseline clinical param-
eters failed to discriminate between patients showing high, 
moderate, or low compliance.4 This second attempt enquired 
about attitudes towards treatment that might characterize 
poor compliers. This was explored with the EDSQ that 
examines patients’ views about eye drop treatments, with 
aspects relevant to glaucoma, in order to explore compli-
ance profiles. BN analysis was applied successfully to the 
EDSQ scores characterizing three compliance levels. The 
analysis identified two subgroups of patients at high risk of 
poor compliance when measured objectively; first, patients 
younger than 77.5 years of age with low self-declared compli-
ance and an unsatisfactory relationship with their physician 
and, second, patients older than 77.5 years of age with high 
self-declared compliance and an unsatisfactory relationship 
with their physician.
These results confirm studies showing that communication 
and a good patient–physician relationship that provides 
education for patients about glaucoma and its treatment 
is essential for compliance.8,11–13,16 Conversely, because 
patients rely strongly on their doctor for such information, 
a poor relationship was identified as a major barrier to 
compliance.8,11,12,16–18
Interestingly, our results are not fully consistent with 
previous publications with respect to age and other factors 
associated with compliance. First, we found a relation-
ship between age and compliance that was not observed in 
several studies.11,14,18,20,34 However, in contrast with customary 
statistical methods, we used BN based on association tables 
and inevitably model interaction effects between variables. 
Consequently, age was included with other factors (patient–
clinician relationship and self-declared compliance), and 
was thereby related to objectively identified compliance 
(Travalert). Methods used in previous work may not have 
revealed such interaction effects.
Second, trust in the efficacy of treatment (closely related 
to our positive beliefs score) has been previously related 
to compliance,8,12 as have been concerns about disease5 
and treatment convenience.12,34 Our BN analysis linked no 
equivalent EDSQ item directly to compliance. This difference 
may be explained by specific features of BN.
In our study, the absence of direct links between Travalert-
identified compliance and previously identified components 
of compliance can be explained by the notion of conditional 
independence. The finding that only age, self-declared com-
pliance scores, and patient–clinician relationship scores were 
Table  3  Associations  between  patient–clinician  relationship 
scores and treatment concern scores
Treatment concerns  
score
Patient–clinician relationship 
score (n, %)
#67.5 .67.5
#24.197 9 (8.1) 101.5a (91.9)
.24.197 24 (36.6) 41.5a (63.4)
Total 33 (18.8) 143 (81.2)
Notes:  a0.5  frequencies  due  to  missing  data  imputation.  Eye-Drop  Satisfaction 
Questionnaire scores ranged from 0 to 100. Higher dimension scores reflect more 
of the attribute implied by the name (eg, higher concern about treatment, a better 
clinician relationship). Threshold values fixed by the Bayesian network algorithm.
Table 4 Associations between positive beliefs scores and treatment 
convenience scores
Treatment convenience  
score
Positive beliefs score (n, %)
#61.335 .61.335
#69.397 38.5a (51.0) 37 (49.0)
.69.397 20.5a (20.4) 80 (79.6)
Total 59 (33.5) 117 (66.5)
Notes:  a0.5  frequencies  due  to  missing  data  imputation.  Eye-Drop  Satisfaction 
Questionnaire  scores  ranged  from  0  to  100.  Higher  dimension  scores  reflect 
more of the attribute implied by the name. Threshold values fixed by the Bayesian 
network algorithm.
Table 5 Associations between declared compliance scores and 
positive beliefs scores
Positive beliefs score Declared compliance score (n, %)
#89.583 .89.583
,61.335 31 (52.5) 28 (47.5)
.61.335 18 (15.4) 99 (84.6)
Total 49 (27.8) 127 (72.2)
Notes: Eye-Drop Satisfaction Questionnaire scores ranged from 0 to 100. Higher 
dimension scores reflect more of the attribute implied by the name. Threshold 
values fixed by the Bayesian network algorithm.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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linked directly to compliance indicates that compliance was 
conditionally independent of other BN variables. It does not 
mean that other variables were not involved in compliance 
indirectly. In fact, BN showed these scores to be indirect 
components of compliance by linkage through other vari-
ables. Thus, BN may provide a more precise description 
of the compliance process, and may show how different 
conceptions of compliance, finally impact on the behavior 
of glaucoma patients.
This study applied advanced techniques for data analy-
sis, ie, BN and oversampling. The rationale for BN was that 
patients’ satisfaction and compliance with treatment is a 
multidimensional phenomenon calling for methods that take 
complexity into account. Also, an oversampling strategy had 
to be introduced. The numeric imbalance between compliant 
patients and poorly compliant patients jeopardized the quality 
of our results, so we considered possible simple solutions to the 
problem, ie, oversampling (artificially increasing the size of 
the smallest group by random sampling and replacement), and 
undersampling (reducing the size of the largest group by ran-
domly deleting cases). Despite evidence that undersampling 
has previously shown better results35,36 and that oversampling 
may increase the risk of overfitting,37 the latter method had to 
be used because of our very small dataset, ie, only 113 patients 
Table 6 Associations between Travalert® identified compliance and self-declared compliance scores, patient–clinician relationship 
scores, and age
Self-declared 
compliance score
Age Patient–clinician 
relationship score
Travalert identified compliance (n, %)
Low Moderate/high
#89.583 #77.5 #67.5 7 (87.5) 1 (12.5)
#89.583 #77.5 .67.5 24 (66.7) 12 (33.3)
#89.583 .77.5 #67.5 0 (0.0) 0.5a (100.0)
#89.583 .77.5 .67.5 3 (66.7) 1.5a (33.3)
.89.583 #77.5 #67.5 8 (55.2) 6.5a (44.8)
.89.583 #77.5 .67.5 19 (24.7) 58 (75.3)
.89.583 .77.5 #67.5 10 (100.0) 0 (0.0)
.89.583 .77.5 .67.5 17 (66.7) 8.5a (33.3)
Total 88 (50.0) 88 (50.0)
Notes: a0.5 frequencies are due to missing data imputation. Eye-Drop Satisfaction Questionnaire scores ranged from 0 to 100. Higher dimension scores reflect more of the 
attribute implied by the name. Threshold values fixed by the Bayesian network algorithm.
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Figure 2 A posteriori probabilities of low compliance, according to age, patient–clinician relationship, and self-declared compliance. A priori probability was fixed at 50% 
as the result of the over sampling. Blue vertical bars represents a posteriori probabilities, once EDSQ results were estimated. The greater the distance from the red line to 
the bar chart, the greater the BN added value at determining patient compliance. EDSQ scores ranged from 0 to 100. Higher dimension scores reflect more of the attribute 
implied by the name. Threshold values fixed by the BN algorithm.
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provided sufficient data to construct a compliance profile, and 
the low-compliance group included only 25 patients.
The age and gender ratios of our sample are close to 
those of glaucoma-treated patients in France.38 Whether these 
results could apply to other countries (within or even outside 
the European Union) is debatable, especially when some 
factors appeared to be culture-dependent, such as confidence 
in the doctor. Also, economic factors might play a role in 
this older population. For example, reimbursement status 
in France is almost independent of retirement, which is not 
the case in other countries. On the one hand, the EDSQ was 
developed according to a conceptual model and it was tested 
that this model applied in other countries. On the other hand, 
patient data collection will be requested to check whether 
this hypothesis will remain empirically valid.
We acknowledge that our study has certain limitations. 
First, our analyses were performed on a relatively small 
number of patients. Thus, the BN structure may have been 
biased by a few noncompliers. Also, only 113 (63.1%) 
patients of 179 were investigated for both EDSQ and com-
pliance, possibly leading to selection bias, although internal 
validity (explored by the BN) might be less affected. We have 
not performed sample size estimation for a protocol aimed 
at confirming our findings without using the oversampling 
method. Microsimulation based on the BN described and 
accounting for the prevalence of poor compliance might 
be useful to fix the size of a future experiment. Second, 
we followed up patients who were willing to use Travalert, 
and these patients might have different behavior from that 
of the general population. Third, the results reported were 
observed in patients treated either by Travatan® or DuoTrav®, 
so extrapolation of the BN results to other drugs needs to 
be documented. Fourth, only one approach was adopted to 
elicit a BN structure. The small sample size of our survey 
did not allow for a test-retest-validation process. Hence, the 
resulting structure should be viewed with caution, and new 
surveys should be conducted to validate our findings. Also, 
it might well be worthwhile to undertake a validation of 
the structure, replicating our analysis with other structural 
learning algorithms and larger datasets. Finally, a question 
must be raised concerning our objective assessment of 
compliance. Electronic devices have been recognized as 
an efficient way to assess compliance,19 but they may have 
limitations. In particular, one reason for poor compliance 
encountered by some patients is difficulty with instilling 
eye drops correctly.13,18 Because Travalert counts only the 
number of drops dispensed by a bottle, and cannot verify 
that they are correctly instilled, our study could not control 
this aspect of the research. Moreover, patients knew they 
were being observed, which might have impacted on their 
behavior. However, in a previous paper, we reported that 
these poor compliers had a significant increase in IOP (by 
about 2 mmHg) in comparison with good compliers. There-
fore, this observational bias might have underestimated the 
impact of compliance on IOP control. Consequently, this BN 
identified poor compliers who had a lack of IOP control of at 
least 2 mmHg, which is a clinically relevant difference. Our 
sample size was not big enough to explore both the impact of 
clinician and patient characteristics on identifying poor com-
pliers. In this approach, we favored data collected at a patient 
level. Additional research might be useful for identifying the 
correct information to be collected at an ophthalmologist 
level. These limitations warrant a cautious interpretation of 
our results and further work with a larger sample size and 
test-retest methodology to confirm the findings.
Conclusion
In conclusion, the application of BN to EDSQ data made 
it possible to re-examine the complex process of treatment 
compliance in glaucoma patients and to identify reasons 
for poor compliance. The crucial message for physicians 
from our results is that, before switching glaucoma treat-
ments because of poor IOP control, they should consider 
the patient’s age, self-declared compliance, and how best to 
educate the patient about glaucoma and its treatment.
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